138 reports of this reaction
1.4% of all TASIMELTEON reports
#17 most reported adverse reaction
PRODUCT DOSE OMISSION is the #17 most commonly reported adverse reaction for TASIMELTEON, manufactured by Vanda Pharmaceuticals Inc.. There are 138 FDA adverse event reports linking TASIMELTEON to PRODUCT DOSE OMISSION. This represents approximately 1.4% of all 9,924 adverse event reports for this drug.
Patients taking TASIMELTEON who experience product dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION is a less commonly reported adverse event for TASIMELTEON, but still significant enough to appear in the safety profile.
In addition to product dose omission, the following adverse reactions have been reported for TASIMELTEON:
The following drugs have also been linked to product dose omission in FDA adverse event reports:
PRODUCT DOSE OMISSION has been reported as an adverse event in 138 FDA reports for TASIMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION accounts for approximately 1.4% of all adverse event reports for TASIMELTEON, making it a notable side effect.
If you experience product dose omission while taking TASIMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.